ADMA Biologics

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Earnings data Q3 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018

ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024

ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

RAMSEY, N.J. and BOCA RATON, Fla., Dec.  17, 2019  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). ADMA’s addition the NBI will become effective prior to market open on Monday, December 23, 2019.

ADMA Biologics Added to NASDAQ Biotechnology Index

Adam Grossman, President & CEO, to Join PPTA North America Board of Directors Adam Grossman, President & CEO, to Join PPTA North America Board of Directors

ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association

ADMA Biologics recently publicized their first commercial sale of their IVIG product, ASCENIV. Now, the company has three commercial products and multiple sources of revenue.

ADMA Biologics Adds ASCENIV's First Sale To A Strong List Of 2019 Accomplishments

RAMSEY, N.J. and BOCA RATON, Fla., Oct.  22, 2019  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced that it has been named Company of the Year by BioFlorida, in recognition of ADMA’s significant achievements over the past year.

ADMA Biologics Named Company of the Year by BioFlorida

RAMSEY, N.J. and BOCA RATON, Fla., Oct.  21, 2019  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced the first commercial sales of ASCENIV (formerly known as RI-002).  ASCENIV received approval from the U.S. Food and Drug Administration (“FDA”) on April 1, 2019.

ADMA Biologics Announces First Commercial Sales of ASCENIV™

RAMSEY, N.J. and BOCA RATON, Fla., Oct.  17, 2019  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and the prevention of certain infectious diseases, today announced the publication of an article describing the manufacturing process optimization of ADMA’s Intravenous Immunoglobulin (“IVIG”) products, BIVIGAM® and ASCENIV™ in the peer reviewed journal Immunotherapy.

ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

RAMSEY, N.J. and BOCA RATON, Fla., Oct.  07, 2019  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that a poster presentation was given at IDWeek 2019, the combined annual meeting of IDSA, SHEA, HVMA and PIDS in Washington, D.C. The poster detailed data obtained from the compassionate use of ASCENIV™ (formerly referred to as RI-002) in the treatment of Respiratory Syncytial Virus (“RSV”) infection in two immunocompromised children.

ADMA Biologics Announces Data Presented at IDWeek 2019

RAMSEY, N.J. and BOCA RATON, Fla., Sept.  23, 2019  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops specialty plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces that Adam Grossman, President and Chief Executive Officer, and Brian Lenz, Executive Vice President and Chief Financial Officer, are scheduled to present a corporate overview at the Cantor Global Healthcare Conference, to be held October 2-4, 2019, at the InterContinental New York Barclay, in New York City.  ADMA is scheduled to present on Wednesday, October 2, 2019 at 10:40 AM ET.

ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

ADMA Biologics has re-launched their IVIG product, BIVIGAM, during a nationwide IG shortage. With ASCENIV's launch approaching, I expect ADMA to capitalize on the current market conditions.

ADMA: Ready To Capitalize On The IVIG Shortage

RAMSEY, N.J. and BOCA RATON, Fla., Aug.  22, 2019  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures and markets three approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases, announces the commercial relaunch and its first commercial sales of BIVIGAM®.

ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

For a company that just racked up two significant regulatory wins, ADMA Biologics Inc.

ADMA Biologics: Selloff Creates Buying Opportunity

Aurora Cannabis

Cleveland-Cliffs

Evofem Biosciences Inc

Inseego

OrganiGram Holdings Inc.

Zynga

These seven cheap stocks under $10 all have massive upside potential according to Wall Street's top analysts.
The post 7 High-Quality Cheap Stocks to Buy With $10 appeared first on InvestorPlace.

7 High-Quality Cheap Stocks to Buy With $10

After years of struggle, ADMA Biologics appears at last to be poised for bigger things.

ADMA Biologics Is De-Risked and Ready to Rise

Shares have lost over a third of their value during the past three years.

ADMA Biologics: Significant Derisking, Product Launches In Second Half Of The Year

Since April, ADMA has won approval for two IVIG products, Asceniv and Bivigam, as well as approval to manufacture them in its vertically integrated facility.

ADMA Biologics: Under-The-Radar Biotech With Huge Potential Upside

Advaxis

Novartis

Roche Holding AG

Here's a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Advaxis Offering, Roche's Spark Tender Offer Extended, Ascendis Earnings

Microcap specialty pharma company ADMA Biologics Inc. advanced in the last two trading days in anticipation of a binary event, and with the event materializing in favor of the company, the stock has taken another leg up.

ADMA Biologics Rips Higher On FDA Nod For Immunodeficiency Therapy

Shares of ADMA Biologics Inc. rocketed 54% in very active premarket trade Tuesday.

ADMA Biologics' stock rockets on heavy volume after FDA approval of immunodeficiency treatment

Back on December 19th, ADMA Biologics (ADMA) received a complete response letter "CRL" from the FDA concerning their PAS for BIVIGAM.

News for ADMA Biologics Stock (ADMA)